Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PHASE 2, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF PD 0332991 (ORAL CDK 4/6 INHIBITOR) MONOTHERAPY AND PD 0332991 IN COMBINATION WITH THE ENDOCRINE THERAPY TO WHICH THE PATIENT HAS PROGRESSED IN THE PREVIOUS LINE FOR ER-POSITIVE, HER2-NEGATIVE POST-MENOPAUSAL ADVANCED BREAST CANCER PATIENTS

Next Previous
X
Search
Trial Profile

PHASE 2, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF PD 0332991 (ORAL CDK 4/6 INHIBITOR) MONOTHERAPY AND PD 0332991 IN COMBINATION WITH THE ENDOCRINE THERAPY TO WHICH THE PATIENT HAS PROGRESSED IN THE PREVIOUS LINE FOR ER-POSITIVE, HER2-NEGATIVE POST-MENOPAUSAL ADVANCED BREAST CANCER PATIENTS

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Palbociclib (Primary) ; Anastrozole; Exemestane; Fulvestrant; Letrozole
  • Indications Adenocarcinoma; Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms TREnd

    • Most Recent Events

    • 14 Jan 2020 Results assessing thymidine kinase activity as a biomarker in patients with metastatic breast cancer treated with palbociclib, published in the Clinical Cancer Research.
    • 03 Apr 2019 Results presented at the 110th Annual Meeting of the American Association for Cancer Research
    • 11 Jun 2018 Results examining the activity of palbociclib published in the Annals of Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top